Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
IGC Pharma, Inc. Common Stock
(NY:
IGC
)
0.3115
+0.0315 (+11.25%)
Streaming Delayed Price
Updated: 1:22 PM EDT, Apr 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about IGC Pharma, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
April 07, 2026
Via
ACCESS Newswire
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
March 30, 2026
Via
ACCESS Newswire
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
March 28, 2026
Via
ACCESS Newswire
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning
March 25, 2026
Via
ACCESS Newswire
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
March 19, 2026
Via
ACCESS Newswire
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
March 18, 2026
Via
ACCESS Newswire
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
February 26, 2026
Via
ACCESS Newswire
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
February 24, 2026
Via
ACCESS Newswire
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
February 23, 2026
Via
ACCESS Newswire
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
February 17, 2026
Via
ACCESS Newswire
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
February 12, 2026
Via
ACCESS Newswire
IGC Pharma Announces Equity Research Update by Alliance Global Partners
February 10, 2026
Via
ACCESS Newswire
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
February 09, 2026
Via
ACCESS Newswire
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
February 02, 2026
Via
ACCESS Newswire
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
January 22, 2026
Via
ACCESS Newswire
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
January 12, 2026
Via
ACCESS Newswire
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
January 06, 2026
Via
ACCESS Newswire
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
January 05, 2026
Via
ACCESS Newswire
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
December 19, 2025
Via
ACCESS Newswire
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
December 15, 2025
Via
ACCESS Newswire
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
December 10, 2025
Via
ACCESS Newswire
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
December 09, 2025
Via
ACCESS Newswire
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
December 02, 2025
Via
ACCESS Newswire
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
November 25, 2025
Via
ACCESS Newswire
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
November 17, 2025
Via
ACCESS Newswire
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
November 13, 2025
Via
ACCESS Newswire
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
November 10, 2025
Via
ACCESS Newswire
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
November 03, 2025
Via
ACCESS Newswire
IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
October 22, 2025
Via
ACCESS Newswire
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
October 14, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
